Ark Bio is a medical technology company
Ark is an end-to-end solution provider focused on cancer early detection. By harnessing advanced data science and proprietary miRNA detection technology, Ark develops non-invasive and cost-effective blood tests to detect early stage cancers before clinical symptoms appear. The company collaborates extensively with top medical research institutions globally and is spearheading Asia’s largest miRNA clinical studies targeting more than 50,000 participants. Ark is headquartered in Singapore, with R&D, manufacturing and clinical diagnostic operations in China and USA.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 27, 2018 | Series A | $40M | 1 | Gaorong Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Gaorong Capital | Yes | Series A |